Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cybin (TSE:CYBN)
NEO-L:CYBN
Holding TSE:CYBN?
Track your performance easily
CYBN Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.14 - C$0.14
Previous CloseC$0.14
Volume0.00
Average Volume (3M)N/A
Market Cap
C$1.97M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Feb 18, 2025EPS Estimate
-C$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.14
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$144.96Price Target Upside107279.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cybin News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe 12-month efficacy data for CYB003 in major depressive disorder is described as stellar, with significant improvements observed in patients.
Market PotentialIf later-stage trial results are similar to current findings, CYB003 could become a game-changing adjunct treatment for major depressive disorder.
Safety ProfileCYB003 has demonstrated a consistently favorable safety profile, with no new adverse events reported.
Bears Say
Clinical Development And Regulatory RisksRisks include clinical development risk tied to CYB003, CYB004, and CYB005, along with competitor and regulatory risks.
Financial PerformanceCYBN's operating expenses exceeded expectations due to significant share-based compensation related to recent senior hires and milestones achieved.
Regulatory DelaysCompass Pathways provided a business update, disclosing delays to the top-line results release for their COMP360 phase 3 trials.
---
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was C$0.14 and its highest was C$0.14 in the past 12 months.
What is Cybin’s market cap?
Currently, no data Available
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Feb 18, 2025 which is in 89 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Nov 11, 2024. The company reported -C$2.86 earnings per share for the quarter, missing the consensus estimate of -C$0.035 by -C$2.825.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -C$1.05.
How many shares outstanding does Cybin have?
Cybin has 19,991,910 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -C$2.86 in its last earnings report, missing expectations of -C$0.035. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in TSE:CYBN
---
Cybin Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$144.96 (107279.33% Upside)
C$144.96 (107279.33% Upside)
Blogger Sentiment
Bullish
TSE:CYBN Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.9%
Last 30 Days ▲ 21.9%
Last 30 Days ▲ 21.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2374.50%
12-Months-Change
Fundamentals
Return on Equity
-80.93%
Trailing 12-Months
Asset Growth
355.68%
Trailing 12-Months
Company Description
Cybin
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
---
CYBN Stock 12 Month Forecast
Average Price Target
C$144.96
▲(107279.33% Upside)
Technical Analysis
Cybin
―
Mind Medicine
―
COMPASS Pathways
―
ATAI Life Sciences
―
Relmada Therapeutics
―
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
12/22 ratings generated profit
1 Year Average Return
+310.82%
reiterated a buy rating 3 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +310.82% per trade.
---